Bull Market Turns 16: Why Investors Should Brace for a 'Difficult Decade' Ahead.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy BYND?
Source: MarketWatch
Investor Sentiment: Many investors are buying the dip in equities, driven by factors like reasonable economic growth and falling interest rates, despite concerns over high valuations.
Secular Trends: According to Phillip Colmar, U.S. equities are experiencing a 16-year secular bull market that began in 2009, influenced by long-term trends that span multiple economic cycles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BYND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BYND
Wall Street analysts forecast BYND stock price to rise
4 Analyst Rating
0 Buy
1 Hold
3 Sell
Moderate Sell
Current: 0.610
Low
0.80
Averages
0.93
High
1.00
Current: 0.610
Low
0.80
Averages
0.93
High
1.00
About BYND
Beyond Meat, Inc. is a plant-based meat company offering a portfolio of plant-based meats. The Company sells a range of plant-based meat products across its three core platforms of beef, pork and poultry. The primary components of animal-based meat are amino acids, lipids, carbohydrates, trace minerals and water, which are not exclusive to animals and are plentiful in plants. Its beef platform products contain protein primarily derived from one or a combination of pea protein, rice protein, faba bean protein and wheat gluten. Its pork platform products include Beyond Sausage, Beyond Breakfast Sausage Patties, Beyond Breakfast Sausage Links and Beyond Sausage Crumbles. Its poultry platform consists of products that mimic animal-based chicken in its various merchandised forms, including chicken tenders, chicken nuggets and popcorn chicken. Its primary products under its poultry platform include Beyond Chicken Tenders, Beyond Chicken Nuggets and Beyond Popcorn Chicken.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Nike Earnings Forecast: Nike (NKE) is expected to report an earnings per share of $0.29 for the quarter ending February 28, 2026, representing a 46.30% decrease compared to the same quarter last year, indicating increased competitive pressure despite beating expectations consistently over the past year.
- PVH Earnings Outlook: PVH is forecasting an earnings per share of $3.30 for the quarter ending January 31, 2026, reflecting a modest 0.92% increase year-over-year, demonstrating its stable market position as it has consistently exceeded market expectations in the past year.
- RH Earnings Growth: RH anticipates an earnings per share of $2.21 for the quarter ending January 31, 2026, marking a significant 39.87% year-over-year increase, showcasing strong business growth potential that may attract more investor interest.
- nCino Earnings Prediction: nCino expects an earnings per share of $0.06 for the quarter ending January 31, 2026, representing a remarkable 250.00% increase compared to the same quarter last year, which could help restore market confidence after previous underperformance.
See More
- Oil Price Volatility: Crude oil prices surged 55% in March following Trump's threat to 'take the oil in Iran,' marking the largest monthly gain ever, which has heightened concerns about the potential impact on the U.S. economy and market sentiment.
- Government Shutdown Impact: Trump signed an executive order to ensure TSA employees are paid after Congress failed to reach a deal, which may lead to longer security wait times and higher airfare for travelers, further affecting consumer confidence.
- Tech Industry Legal Risks: Meta's two courtroom defeats reveal the legal liabilities tech companies face when researching product impacts, which could have significant implications for the AI industry, prompting firms to reassess the risks versus rewards of such research investments.
- Pharmaceutical Collaboration: Eli Lilly's $2.75 billion deal with Insilico Medicine aims to bring AI-developed drugs to the global market, which not only boosted Lilly's stock price but also highlights the rapidly growing potential of AI applications in the pharmaceutical sector.
See More
- Oil Price Surge: Crude oil prices skyrocketed by 55% in March following Trump's threat to seize Iranian oil, marking the largest monthly gain ever, which pressures the U.S. economy and forces companies to adjust pricing strategies to cope with rising costs.
- Market Recovery Signal: Despite the S&P 500 and Nasdaq Composite experiencing their worst week of 2026, stock futures rose after Trump indicated “great progress” in negotiations with Iran, reflecting investor optimism about market recovery.
- TSA Employee Pay Restoration: Trump signed an executive order ensuring Transportation Security Administration employees will receive pay after Congress failed to reach a deal to end the government shutdown, alleviating traveler frustrations caused by long security wait times.
- AI Drug Development Partnership: Eli Lilly struck a $2.75 billion deal with Insilico Medicine to bring AI-developed drugs to market, enhancing Lilly's market confidence and potentially accelerating the application of AI in the pharmaceutical industry.
See More
- Stock Price Collapse: Beyond Meat has seen its stock price plummet by 99.7% since 2021, with revenue dropping from $464.7 million in 2021 to $326.4 million in 2024, and forecasts predicting just $275.9 million in 2025, indicating a severe financial crisis for the company.
- Escalating Cash Burn: Despite cost-cutting efforts, Beyond Meat's annual operating losses remain in the nine-digit range, leading to persistent cash flow issues that forced the company to rely on a $1.15 billion convertible note offering in 2021 to sustain operations.
- Shareholder Dilution Risk: The need to redeem convertible notes has significantly increased Beyond Meat's share count, resulting in shareholder dilution and exacerbating the downward pressure on the stock price, which now trades below $1 and faces delisting risk from Nasdaq.
- Reverse Stock Split Possibility: The company may undertake a reverse stock split to maintain its Nasdaq listing, but this action will not improve its fundamentals and could make it easier for bearish investors to short the stock, highlighting the company's inability to address high losses and declining sales.
See More
- Stock Price Collapse: Beyond Meat's stock has plummeted from over $230 in 2019 to under $1, with a market cap of just $289 million, indicating extreme bearish sentiment and a looming delisting risk.
- Declining Revenue: The company's total revenue has dropped from $464.7 million in 2021 to $326.4 million in 2024, with forecasts predicting only $275.9 million in 2025, highlighting a significant decrease in market demand and increasing competitive pressures.
- Escalating Operating Losses: Despite cost-cutting measures, Beyond Meat's annual operating losses remain in the nine-digit range, leading to severe cash burn and forcing the company to rely on proceeds from a $1.15 billion convertible note offering in 2021 to sustain operations.
- Reverse Stock Split Ineffective: Even if a reverse stock split occurs to maintain its Nasdaq listing, fundamental issues such as high losses and declining sales will persist, making it unlikely for the stock to recover significantly in the short term.
See More
- Stock Price Collapse: Beyond Meat's stock has plummeted from over $230 in 2019 to under $1, representing a staggering 99.7% decline, reflecting extreme bearish sentiment and the looming threat of delisting.
- Revenue Decline: The company's total revenue has dropped from $464.7 million in 2021 to $326.4 million in 2024, with forecasts predicting just $275.9 million in 2025, indicating a severe weakening in market demand that critically impacts financial health.
- Escalating Operating Losses: Despite cost-cutting measures, Beyond Meat's annual operating losses remain in the nine-digit range, leading to significant cash burn and forcing reliance on a $1.15 billion convertible note offering from 2021 to sustain operations.
- Reverse Stock Split Ineffectiveness: Even if a reverse stock split occurs to maintain its Nasdaq listing, fundamental issues such as shareholder dilution and ongoing losses will persist, making it difficult for the stock price to recover, thus investors should carefully consider their positions.
See More











